Treatment of cardiovascular and cerebrovascular diseases Traditional Chinese medicine has already produced heavy-duty varieties such as Compound Danshen Dripping Pills and Step-length Brain-Heart-Throughs. There is no new space for Chinese medicine. There is a peculiar phenomenon: In the prescription drug market, traditional Chinese medicine is a short-suffering person, almost no nationality, in addition to cardiovascular and cerebrovascular diseases outside the Chinese medicine market. Compound Danshen Dripping Pills, Diao Xinxuekang and other oral preparations, Ginkgo biloba, Breviscapine and other injection varieties, sales have achieved hundreds of millions, and even close to 500 million yuan, 1 billion yuan mark, occupying half of the cardiovascular and cerebrovascular disease drug market.
Why does the use of Western medicine as the mainstream of clinical terminals, other Chinese medicine varieties have fallen steadily, cardiovascular and cerebrovascular disease treatment of Chinese medicine has come up with a big name? Simple summary: There are huge consumer groups, the market is rapidly expanding, and the growth rate is above 25%; Cardiovascular and cerebrovascular diseases have traditional OTC characteristics; Chinese consumers have deep-rooted traditional Chinese medicine culture, which also creates space for the marketing communication of such products. Chinese medicine products have demonstrated exact clinical efficacy in the treatment of cardiovascular and cerebrovascular diseases; companies are adept at marketing innovation, as well as close collaboration and strong execution and service capabilities in the channel.
The achievements of cardiovascular and cerebrovascular diseases in the treatment of traditional Chinese medicine are reassuring. Can the Chinese medicine produce the next “Compound Danshen Dripping Pill� In what areas have this potential? What kind of varieties and marketing methods are needed? Compared with traditional Chinese medicines for the treatment of cardiovascular and cerebrovascular diseases, we believe that there are four potential reasons for the expansion of orthopaedic Chinese medicines, from the comprehensive analysis of capacity, breed, cognition, efficacy, competition, and end use.
First, the orthopedic market has a large enough capacity and continues to expand. The clinical needs are urgent.
To date, the total number of arthritis and musculoskeletal diseases that have been identified exceeds 120, including major categories such as osteoarthritis, rheumatoid arthritis, and osteoporosis. According to relevant statistics, the incidence of osteoarthritis in people over the age of 60 is 78.5%, and 90% of people over the age of 70 have symptoms of knee cartilage degradation, joint pain and arthritis, and the total number of patients is over 100 million. With the advent of aging society, the market for degenerative osteoarthritis will continue to expand.
In addition, the urgent need for clinical treatment of orthopedic diseases can quickly realize the change from demand to market. Statistics show that osteoarticular diseases account for 20% of outpatient cases. From the perspective of the world market, global sales of anti-rheumatic drugs reached US$9.5 billion in 2002. In 2003, the sales volume of Wanlor reached US$2.5 billion, which once represented 10% of Mesa’s total annual sales. Pfizer’s global sales are listed for 5 years. It reached 1.9 billion U.S. dollars. This shows that the market is huge.
Second, the adverse reactions of Western medicine make Chinese medicines have market space. Rheumatism and arthritis commonly used western medicine include hormones, non-steroidal anti-inflammatory drugs, common analgesics, and coxibs. Although these drugs are effective, but because of the long-term use of such diseases, Western medicine side effects of the larger drawbacks, some consumers have concerns. If the non-steroidal anti-inflammatory drugs have a large gastrointestinal response, severe ulcers, bleeding, and perforation may occur. According to statistics, the use of these drugs induced gastrointestinal diseases can increase medical expenses by 30%. In addition, clinical studies have shown that the use of non-steroidal anti-inflammatory drugs will inhibit the synthesis of collagen matrix, and some can directly destroy articular chondrocytes and accelerate osteoarthritis. Undoubtedly, this limits the clinical use of the drug. In fact, the market share of such products is also shrinking. Other types of drugs have also been plagued by side effects. For example, Vioxx was recalled for cardiovascular events and Celebrity was questioned.
Thirdly, similar to cardiovascular and cerebrovascular diseases, rheumatism, osteoarthritis, etc. also belong to the category of chronic diseases. Patients need long-term medications, and traditional Chinese medicine has a deeper cognitive foundation for the treatment and safety of bone diseases. Facilitate market development.
Fourth, the health insurance system is sound and the third terminal is booming, activating the market purchasing power. According to survey data, at present, more than 60% of rheumatoid patients in China are concentrated in rural areas. This huge potential market demand, along with the gradual release of new rural cooperative medical policies, converts demand into purchasing power, allowing Orthopaedic Chinese medicine to have a huge “market. imagination.
It is based on the above background that orthopedic Chinese medicine is expected to become a valuable gold mine. From this perspective, we can look at OTC and health care products. Since 2003, we have used a variety of traditional Chinese medicine products for the rheumatoid bone disease market to create “concepts†from marketing and use newspaper soft papers, powerful promotions, and terminal activities. Above 100 million yuan, the premise of its success is the huge consumer demand and desire for treatment.
Why does the use of Western medicine as the mainstream of clinical terminals, other Chinese medicine varieties have fallen steadily, cardiovascular and cerebrovascular disease treatment of Chinese medicine has come up with a big name? Simple summary: There are huge consumer groups, the market is rapidly expanding, and the growth rate is above 25%; Cardiovascular and cerebrovascular diseases have traditional OTC characteristics; Chinese consumers have deep-rooted traditional Chinese medicine culture, which also creates space for the marketing communication of such products. Chinese medicine products have demonstrated exact clinical efficacy in the treatment of cardiovascular and cerebrovascular diseases; companies are adept at marketing innovation, as well as close collaboration and strong execution and service capabilities in the channel.
The achievements of cardiovascular and cerebrovascular diseases in the treatment of traditional Chinese medicine are reassuring. Can the Chinese medicine produce the next “Compound Danshen Dripping Pill� In what areas have this potential? What kind of varieties and marketing methods are needed? Compared with traditional Chinese medicines for the treatment of cardiovascular and cerebrovascular diseases, we believe that there are four potential reasons for the expansion of orthopaedic Chinese medicines, from the comprehensive analysis of capacity, breed, cognition, efficacy, competition, and end use.
First, the orthopedic market has a large enough capacity and continues to expand. The clinical needs are urgent.
To date, the total number of arthritis and musculoskeletal diseases that have been identified exceeds 120, including major categories such as osteoarthritis, rheumatoid arthritis, and osteoporosis. According to relevant statistics, the incidence of osteoarthritis in people over the age of 60 is 78.5%, and 90% of people over the age of 70 have symptoms of knee cartilage degradation, joint pain and arthritis, and the total number of patients is over 100 million. With the advent of aging society, the market for degenerative osteoarthritis will continue to expand.
In addition, the urgent need for clinical treatment of orthopedic diseases can quickly realize the change from demand to market. Statistics show that osteoarticular diseases account for 20% of outpatient cases. From the perspective of the world market, global sales of anti-rheumatic drugs reached US$9.5 billion in 2002. In 2003, the sales volume of Wanlor reached US$2.5 billion, which once represented 10% of Mesa’s total annual sales. Pfizer’s global sales are listed for 5 years. It reached 1.9 billion U.S. dollars. This shows that the market is huge.
Second, the adverse reactions of Western medicine make Chinese medicines have market space. Rheumatism and arthritis commonly used western medicine include hormones, non-steroidal anti-inflammatory drugs, common analgesics, and coxibs. Although these drugs are effective, but because of the long-term use of such diseases, Western medicine side effects of the larger drawbacks, some consumers have concerns. If the non-steroidal anti-inflammatory drugs have a large gastrointestinal response, severe ulcers, bleeding, and perforation may occur. According to statistics, the use of these drugs induced gastrointestinal diseases can increase medical expenses by 30%. In addition, clinical studies have shown that the use of non-steroidal anti-inflammatory drugs will inhibit the synthesis of collagen matrix, and some can directly destroy articular chondrocytes and accelerate osteoarthritis. Undoubtedly, this limits the clinical use of the drug. In fact, the market share of such products is also shrinking. Other types of drugs have also been plagued by side effects. For example, Vioxx was recalled for cardiovascular events and Celebrity was questioned.
Thirdly, similar to cardiovascular and cerebrovascular diseases, rheumatism, osteoarthritis, etc. also belong to the category of chronic diseases. Patients need long-term medications, and traditional Chinese medicine has a deeper cognitive foundation for the treatment and safety of bone diseases. Facilitate market development.
Fourth, the health insurance system is sound and the third terminal is booming, activating the market purchasing power. According to survey data, at present, more than 60% of rheumatoid patients in China are concentrated in rural areas. This huge potential market demand, along with the gradual release of new rural cooperative medical policies, converts demand into purchasing power, allowing Orthopaedic Chinese medicine to have a huge “market. imagination.
It is based on the above background that orthopedic Chinese medicine is expected to become a valuable gold mine. From this perspective, we can look at OTC and health care products. Since 2003, we have used a variety of traditional Chinese medicine products for the rheumatoid bone disease market to create “concepts†from marketing and use newspaper soft papers, powerful promotions, and terminal activities. Above 100 million yuan, the premise of its success is the huge consumer demand and desire for treatment.
Food Blenders are small machines that can stir a variety of food, like fruits and vegetables to extract fresh and delicious fruit and vegetable juice. Food Blenders including plastic jar blenders, glass jar belnders, stainless steel jar blenders, rotary switch blenders and push button blenders. Food Blenders work by rotating the blade at the bottom of the jar at a high speed to break the food repeatedly under the action of water flow. Due to its ability to process a variety of foods, neat and tidy, small in size, light in weight, low in noise, high in efficiency, simple in operation, easy to clean, food blenders are popular among families.
Food Blenders,Electric Food Blenders,Smoothies Maker Blender,Baby Food Blender
Flying Electronic Co., Ltd , https://www.jmflyingelectronic.com